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Uromodulin is produced in the thick ascending limb, but
little is known about regulation of its excretion in urine.
Using mouse and cellular models, we demonstrate that
excretion of uromodulin by thick ascending limb cells is
increased or decreased upon inactivation or activation of
the calcium-sensing receptor (CaSR), respectively. These
effects reﬂect changes in uromodulin trafﬁcking and likely
involve alterations in intracellular cyclic adenosine
monophosphate (cAMP) levels. Administration of the CaSR
agonist cinacalcet led to a rapid reduction of urinary
uromodulin excretion in healthy subjects. Modulation of
uromodulin excretion by the CaSR may be clinically
relevant considering the increasing use of CaSR
modulators.
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U romodulin (Tamm-Horsfall protein), the most abun-dant protein excreted in normal urine, is synthesizedin the cells lining the thick ascending limb (TAL) of
the loop of Henle. Convergent studies indicate that uromo-
dulin regulates salt transport and urinary concentration,
protects against kidney stones and urinary tract infections,
and plays roles in acute kidney injury and innate immunity.
Furthermore, the UMOD gene coding for uromodulin has
been associated with a spectrum of rare and common kidney
diseases.1
Although the excretion of uromodulin in urine is known
to ﬂuctuate,2 surprisingly little is known about the regulators
of uromodulin abundance in the kidney and urine. The
correlations between urinary levels of uromodulin and
markers of tubular function3,4 and the potential inﬂuence of
arginine vasopressin5 suggest that factors operating on the
TAL may be involved. The CaSR is a G protein–coupled re-
ceptor expressed in the TAL, where it regulates paracellular
Ca2þ reabsorption through mechanisms that include a dose-
dependent inhibition of intracellular cAMP levels.6,7 Inacti-
vating or activating mutations of the CASR gene lead to rare
hypercalcemia or hypocalcemia disorders, respectively.8 The
latter can be associated with Bartter-like syndrome, sup-
porting the role of CaSR in maintaining the TAL function.9
Whether the renal CaSR regulates uromodulin production
and/or excretion by TAL cells is unknown.
Here we used mouse models with inactivating and acti-
vating mutations in the Casr gene, combined with pharma-
cologic agents and physiological stimuli, to demonstrate that
chronic or acute modulation of the CaSR inﬂuences the
urinary excretion of uromodulin.
We ﬁrst veriﬁed that, in mouse kidney, Umod and Casr
mRNAs are most abundantly expressed in the TAL
(Figure 1a), with distinct apical (uromodulin) and basolateral
(CaSR) distribution in that segment (Figure 1b). Immuno-
blotting on primary cultures of mouse TAL (mTAL) cells
obtained from TAL segments10 demonstrated that they
endogenously express uromodulin and CaSR, NKCC2, and
ROMK and excrete uromodulin into the apical medium
(Figure 1c).
To examine whether the CaSR modulates uromodulin
excretion in vivo, we analyzed mice with activating (CasrNuf/Nuf)
and inactivating (CasrBCH002/þ) mutations in Casr
(Supplementary Figure S1A and S1B). The activating Casr
mutation p.Leu723Gln in CasrNuf/Nuf mice (Supplementary
Figure S1C and S1E)11 results in signiﬁcantly decreased
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plasma Ca2þ and Mg2þ levels, elevated plasma phosphorus
levels, and lower urinary Ca2þ, Mg2þ, and phosphorus levels
compared with Casrþ/þ mice (Supplementary Table S1). The
CasrNuf/Nuf mice excreted signiﬁcantly less uromodulin in
urine than did Casrþ/þ mice, despite similar uromodulin
protein (Figure 1d and Supplementary Figure S2C) and
slightly increased Umod mRNA levels in the kidneys
(Supplementary Figure S2A). The lower urine levels were
reﬂected by a less pronounced apical and more diffuse
intracellular staining for uromodulin in TAL cells of the
CasrNuf/Nuf kidneys (Figure 1e). The Casr p.Ile859Asn inac-
tivating mutation is causing early death in homozygous
CasrBCH002/BCH002 mice, likely because of decreased CaSR
expression (Supplementary Figure S1D and S1F) and severe
hyperparathyroidism and hypercalcemia.12 Heterozygous
CasrBCH002/þ mice showed signiﬁcantly increased blood Ca2þ
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Figure 1 | Distribution of uromodulin and calcium-sensing receptor (CaSR) in the thick ascending limb (TAL) and the effect of CaSR
mutations on uromodulin excretion. (a) Relative mRNA expression proﬁle of Umod and Casr in microdissected glomeruli (Glom), proximal
convoluted tubules (PCT), proximal straight tubules (PST), TAL, distal convoluted tubules (DCT), and collecting ducts (CD) from wild-type
C57BL6J mice. TAL levels are taken as 100%. Glyceraldehyde-3-phosphate dehydrogenase (Gapdh) expression was used for normalization.
Bars indicate means  SEM, n ¼ 6. (b) Immunoﬂuorescent staining showing the apical and basolateral distribution of uromodulin (green) and
CaSR (red), respectively, in TAL proﬁles from mouse kidney. Bar ¼ 100 mm. (c) Western blot analysis showing uromodulin excretion in the apical
medium and endogenous expression of uromodulin, CaSR, NKCC2, and ROMK in mouse TAL (mTAL) cells. Each lane corresponds to the lysate
from a distinct mTAL cell ﬁlter. (d) Western blot analysis of uromodulin in urine samples (U-UMOD) from CasrNuf/Nuf mice harboring an activating
Casr mutation and wild-type Casrþ/þ controls. Loading volume was adjusted according to creatinine concentration; each lane represents a
different animal. The signal was quantiﬁed by densitometry (bars ¼ means  SEM) on n ¼ 4 Casrþ/þ and n ¼5 CasrNuf/Nuf samples, *P < 0.05,
Student t-test. The protein expression levels of uromodulin, NKCC2, and ROMK in whole kidneys of CasrNuf/Nuf versus Casrþ/þ mice are shown
below the corresponding urine samples. b-Actin was used for loading control. (e) Immunoﬂuorescent staining showing the subcellular dis-
tribution of uromodulin (green) and pNKCC2 (red) in kidney sections of Casrþ/þ and CasrNuf/Nuf mice. Bar ¼ 20 mm. The adjacent panel shows
the line-plot analysis of uromodulin distribution in the Casrþ/þ (black) and CasrNuf/Nuf (red) kidneys, with the apical membrane being deﬁned by
the pNKCC2 signal. Dots indicate means  SEM for n ¼ 4 mice. **P < 0.01; ***P < 0.001, Student t-test. (f) Western blot analysis of U-UMOD
from mice harboring an inactivating Casr mutation CasrBCH002/þ and wild-type Casrþ/þ controls. Loading volume was adjusted according to
creatinine concentration; each lane represents a different animal. The signal was quantiﬁed by densitometry (bars ¼ means  SEM) on n ¼ 4
samples in each group, *P < 0.05, Student t-test. The protein expression levels of uromodulin, NKCC2, and ROMK in whole kidneys of CasrBCH002/
þ versus Casrþ/þ mice are shown below the corresponding urine samples. b-Actin was used for loading control. (g) Immunoﬂuorescent staining
showing the subcellular distribution of uromodulin (green) and pNKCC2 (red) in mouse kidney sections of Casrþ/þ and CasrBCH002/þ mice. Bar ¼
20 mm. The adjacent panel shows the line-plot analysis of uromodulin distribution in the Casrþ/þ (black) and CasrBCH002/þ (red) kidneys, with the
apical membrane being deﬁned according to the pNKCC2 signal. Dots indicate means  SEM for n ¼ 4 mice. *P < 0.05, Student t-test. To
optimize viewing of this image, please see the online version of this article at www.kidney-international.org.
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and decreased plasma phosphorus levels (Supplementary
Table S1) and signiﬁcantly higher levels of uromodulin in
urine (Figure 1f), reﬂected by an enhanced apical staining for
uromodulin in TAL cells (Figure 1g) compared with Casr þ/þ
mice. Of note, uromodulin mRNA and protein expression
levels (Supplementary Figure S2B and S2D) were unchanged
in CasrBCH002/þ versus Casrþ/þ kidneys.
We directly tested the effect of CaSR activation on uro-
modulin secretion by using well-established pharmacologic
agents on mTAL cells. Treatment of mTAL cells with the CaSR
agonist (calcimimetic) calindol (10 nM to 1 mM, 16 hours)
induced a strong dose-dependent decrease in transepithelial
voltage (Figure 2a), paralleled by a decrease in the excretion of
uromodulin in the apical medium (Figure 2b) in the absence
of detectable change in the expression of uromodulin in cell
lysates (Supplementary Figure S3A). Short-term treatment (4
hours) of mTAL cells with 100 nM calindol signiﬁcantly
decreased the transepithelial voltage (Figure 2c) and the apical
excretion of uromodulin (Figure 2d) in the absence of
changes of uromodulin, NKCC2, and ROMK in corre-
sponding cell lysates (Supplementary Figure S3B). Activation
of the CaSR by high extracellular Ca2þ (3 mM, 6 hours)
lowered transepithelial voltage (Figure 2e) and also resulted in a
strong reduction of uromodulin excretion (Figure 2f) in the
absence of changes in protein levels of uromodulin, NKCC2,
and ROMK in cell lysates (Supplementary Figure S3D). The
effects of extracellular Ca2þ on voltage and uromodulin
excretion were abolished upon co-incubation with the speciﬁc
CaSR antagonist NPS2143 (1 mM) (Figure 2e and f), which had
no effect on uromodulin excretion in the absence of high
basolateral Ca2þ concentrations (Supplementary Figure S3C).
The potential link between CaSR signaling, uromodulin
excretion, and intracellular cAMP levels is supported by the fact
that calindol (which decreases uromodulin excretion: Figure 2b
and d) prevented the 1-desamino-8d-arginine vasopressin
(dDAVP)-induced rise of intracellular cAMP levels in mTAL
cells (Figure 2g), whereas acute exposure of mTAL cells to
dDAVP (100 nM, 4 hours) (Figure 2h) and to cAMP (50 mM, 4
hours) (Figure 2i) increased uromodulin excretion.
To verify the translational value of the link between CaSR
and uromodulin excretion, we tested the effect of a single
dose (60 mg) of the calcimimetic drug cinacalcet in healthy
subjects (Figure 2j and k). As expected, administration of
cinacalcet induced a rapid increase (þ266%) of urinary cal-
cium excretion that was paralleled by a decrease (–18%) in
urinary excretion of uromodulin.
The data presented here demonstrate for the ﬁrst time that
urinary excretion of uromodulin is modulated by the CaSR
operating in the basolateral membrane of the TAL. The use of
primary mTAL cells with endogenous expression of uromo-
dulin highlights the value of this system to investigate the
biology of uromodulin. The link between CaSR activity and
excretion of uromodulin is evidenced by (i) decreased or
increased urinary uromodulin levels in mice harboring acti-
vating or inactivating mutations of the Casr, respectively; (ii)
decreased uromodulin excretion after activation of the CaSR
in mTAL cells by a speciﬁc CaSR agonist; (iii) a strong
reduction in uromodulin excretion after activation of the
CaSR in mTAL cells by high extracellular Ca2þ; (iv) abolition
of the effects of high extracellular Ca2þ upon treatment of
mTAL cells with the CaSR antagonist NPS2143; and (v) a
signiﬁcant decrease in uromodulin excretion after a single
dose of cinacalcet in healthy subjects.
The fact that the changes in uromodulin excretion are
reﬂected by modiﬁcations of its intracellular distribution
rather than changes in total mRNA and protein levels suggests
that the CaSR may regulate the trafﬁcking of uromodulin.
Activation of the CaSR decreases intracellular cAMP levels,
resulting from both the inhibition of its production and the
stimulation of its degradation.7,13 The cAMP/protein kinase A
pathway is involved in the trafﬁcking of many proteins in
tubular cells, including NKCC2 in the TAL and aquaporin-2
and epithelial sodium channel in the collecting ducts. Our
data show that mTAL cells respond to dDAVP and cAMP by
increasing the apical excretion of uromodulin; conversely,
activation of the CaSR by calindol decreases uromodulin
excretion and prevents the dDAVP-induced rise in cAMP in
mTAL cells. Taken together, these observations support a role
for CaSR-dependent changes in intracellular cAMP levels in
uromodulin trafﬁcking. The speciﬁc production of uromo-
dulin in TAL cells and the association of urine levels of
uromodulin with markers of tubular function3,4 and genetic
variants in KCNJ1/ROMK2 suggest a cell-autonomous regu-
lation. In fact, changes of uromodulin excretion induced by
CaSR modulators in mTAL cells were paralleled by changes in
the transepithelial voltage. The latter is predominantly Kþ
dependent, because the luminal recycling of Kþ via the apical
ROMK channel generates the lumen-positive voltage in TAL.
Extracellular Ca2þ was shown to generate cytochrome P-450
metabolites that inhibit ROMK activity, likely via CaSR
signaling.14 Future studies should decipher the mechanisms
linking CaSR, ROMK, and uromodulin secretion, including a
potential role of the serine protease hepsin.15
In summary, the activation of CaSR modulates the excre-
tion of uromodulin in the urine, probably through post-
translational control of uromodulin trafﬁcking and cAMP
levels in TAL cells. The possibility of modulating urinary
levels of uromodulin may be clinically relevant, considering
the multifaceted role of this protein in health and disease and
the increasing use of pharmacologic modulators of the CaSR.
SHORT MATERIALS AND METHODS
Mouse models
Studies were conducted in C57BL6J mice and CasrNuf/Nuf (11) and
CasrBCH002/þ12 mice, using well-established protocols.16
Human studies
Healthy subjects gave informed consent to test the effect of a single
dose of cinacalcet, 60 mg, on the excretion of uromodulin and cal-
cium in urine.
Urine and blood chemistry
Urine and blood parameters were determined as described.16,17
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Primary cell culture of TAL cells
Primary cell cultures of mTAL cells were obtained and cultured as
described.10 Conﬂuent mTAL monolayers were exposed (basolateral
side) to calindol,18 NPS2143,19 dDAVP, and 3-isobutyl-1-
methylxanthine (IBMX) alone or with cAMP, as detailed in the
supplementary material. Electrophysiology was performed as
described.10 The cAMP levels were determined with the DetectX
Cyclic AMPenzyme immunoassay kit (Arbor Assays, Ann Arbor, MI).
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Figure 2 | Modulating calcium-sensing receptor (CaSR) activity inﬂuences uromodulin excretion in mouse thick ascending limb (mTAL)
cells and healthy subjects. (a–d) Effects of calindol on mTAL cells. (a) Changes in transepithelial voltage (Vte) of mTAL cells treated with
dimethylsulfoxide (DMSO) (white bar, n ¼ 12) and the CaSR agonist calindol (10 nM, 100 nM, or 1 mM to the basolateral side, n ¼ 4–6 for each
condition) for 16 hours. Bars indicate means  SEM. Analysis of variance (ANOVA): P < 0.0001; Tukey’s multiple comparisons test: NS, not
signiﬁcant; **P < 0.01; ****P < 0.0001. Only comparisons with DMSO are shown. (b) Western blot analysis and relative uromodulin levels in the
apical medium of mTAL cells treated with DMSO and 10 nM to 1 mM calindol for 16 hours (basolateral side). Each lane corresponds to 1 different
mTAL cell ﬁlter (n ¼ 4 per condition). Equal volumes were loaded. Quantiﬁcation by densitometry (bars indicate means  SEM). (c) Vte of mTAL
cells treated with DMSO (open symbols) or 100 nM calindol (black symbols) for 4 hours on the basolateral side (n ¼ 5 for each condition), with
(d) corresponding Western blot analysis for uromodulin levels in the apical medium of mTAL cells. Each lane corresponds to a different mTAL
cell ﬁlter. Quantiﬁcation of the signal by densitometry (bars indicate means  SEM), with values expressed relative to control. (b–d) NS, not
signiﬁcant; *P < 0.05; **P < 0.01; ***P < 0.001, Student t-test. (e,f) Effects of extracellular calcium and NPS2143 on mTAL cells. (e) Changes in Vte
of mTAL cells exposed to variable extracellular Ca2þ concentrations (1 mM, n ¼ 6; 3 mM, n ¼ 7), and 3 mM Ca2þ with 1 mM NPS2143 to the
basolateral side (n ¼ 7) for 6 hours. (f) Representative Western blots for uromodulin levels in apical medium of mTAL cells treated with 1 mM
and 3 mM Ca2þ medium, and 3 mM Ca2þ with 1 mM NPS2143 at the basolateral side for 6 hours. Each lane corresponds to a different mTAL cell
ﬁlter. Quantiﬁcation of the signal by densitometry (bars indicate means  SEM), relative to 1 mM Ca2þ (n ¼ 4/5 for each condition). ANOVA: P <
0.0001 for (e) and P ¼ 0.0140 for (f). Tukey’s multiple comparisons test: NS, not signiﬁcant; *P < 0.05; ****P < 0.0001. (g–i) Effects of 1-desamino-
8d-arginine vasopressin (dDAVP) and cyclic adenosine monophosphate (cAMP) on mTAL cells. (g) Intracellular cAMP levels (pmol/ml of lysate)
in mTAL cells treated with DMSO (control), 100 nM dDAVP for 1 hour, and 100 nM dDAVP with 1 mM calindol for 1 hour, all treatments to the
basolateral side (n ¼ 3/4 for each condition). Each value represents an independent ﬁlter. Bars indicate means  SEM. ANOVA: P ¼ 0.0129;
Tukey’s multiple comparisons test: NS, not signiﬁcant; *P < 0.05. Western blot analysis of uromodulin excretion levels in apical medium of mTAL
cells treated with (h) DMSO (control) versus 100 nM dDAVP to the basolateral side (n ¼ 3/4) and (i) with 3-isobutyl-1-methylxanthine (IBMX)
alone (50 mM) versus IBMX þ cAMP (50 mM each) (n ¼ 4) for 4 hours. Quantiﬁcation by densitometry (bars indicate means  SEM) below the
corresponding blots; values are expressed relative to control or IBMX. *P < 0.05; Student t-test. (j,k) Effect of cinacalcet on urinary uromodulin
excretion in humans. (j) Relative changes in urinary uromodulin (left) and calcium (right) levels in healthy volunteers after a single oral ingestion
of 60 mg cinacalcet. Urine samples were collected at baseline and 1 to 2 hours after ingestion of cinacalcet. Uromodulin and calcium levels were
normalized to urinary creatinine (mg/g creatinine) and are shown relative (in percent) to baseline levels. Symbols represent mean values before
and after cinacalcet administration for a given volunteer (n ¼ 4, linked by dashed lines). Box and whiskers (minimum to maximum) represent
the distribution of the individual values before and after administration of cinacalcet. *P < 0.05; Mann-Whitney test. (k) Western blot analysis for
uromodulin in urine samples (U-UMOD) from a representative subject at baseline and after a single dose of 60 mg cinacalcet. Loading volume
was adjusted according to creatinine concentration for each sample.
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Gene and protein expression analyses
Gene and protein expression analyses were performed using primers,
conditions, and antibodies listed in the Supplementary Material.
Statistics
Data are presented as mean  SEM. Two-tailed unpaired Student t-
test, Mann-Whitney test, or analysis of variance with Tukey’s multiple
comparison tests were used for the statistical analysis, as indicated.
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